WithdrawnPhase 1NCT00679744
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis
Studying Gangliosidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Exsar Corporation
- Principal Investigator
- Bijan Almassian, Ph.D.Exsar Corporation
- Intervention
- Pyrimethamine(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2008
Study locations (3)
- New York University, School of Medicine, Department of Neurology, New York, New York, United States
- University Hospitals of Cleveland, Cleveland, Ohio, United States
- Division of Clinical & Metabolic Genetics, Hospital for Sick Children, Toronto, Ontario, Canada
Collaborators
University Hospitals Cleveland Medical Center · NYU Langone Health · The Hospital for Sick Children
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00679744 on ClinicalTrials.govOther trials for Gangliosidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07082543A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 GangliosidosisAzafaros A.G.
- RECRUITINGPHASE1, PHASE2NCT03952637A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT00668187A Natural History Study of the GangliosidosesUniversity of Minnesota